Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series
Our findings suggest that dual targeted therapy may represent a viable approach for patients with refractory disease and multiple immune-mediated conditions, warranting further investigation in larger cohorts.
Authors
- Esperanza Martínez Ruiz
- Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
- Francisco Javier Melgosa Ramos (ORCID: https://orcid.org/0000-0003-2121-6727)
- Virginia Sanz‐Motilva
- Marta Galarreta Pascual
Institutions
- Hospital de Manises (ES)
- Hospital Universitario Lluís Alcanyís (ES)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1007/s13555-025-01569-x
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00